The Beatrice Hunter Cancer Research Institute logo
  • Dr. Adrian Culf, PhD


Research Scientist, Atlantic Cancer Research Institute


Department of Chemistry and Biochemistry, Mount Allison University, N.B. and Université de Moncton, N.B.

Research Interests:

Medicinal Chemistry

Small molecule anti-cancer; peptide-mimic foldamers; synthetic chemistry; automated synthesis

I am interested in making novel molecules that possess non-toxic yet anti-cancer activities. Examples include histone deacetylase 6 inhibitors to limit metastasis and the construction of peptide-mimc foldamers (e.g. peptoids) that interact with protein-protein surfaces in cancer pathways.

Membership Status:

Dr. Culf is a BHCRI Senior Scientist


(506) 869-2020




Atlantic Cancer Research Institute, 35 Providence Street, Moncton, NB, Canada, E1C 8X3


Adrian S. Culf*, Miroslava Čuperlović-Culf, Rodney J. Ouellette, Andreas Decken “Metal-free, acid-catalyzed ortho-directed synthesis of fluorescent anthranilates by substitution of carbodiimides” Org. Lett. 17 (11) 2744-2747 (2015)

Adrian S. Culf, Miroslava Cuperlovic-Culf, Daniel Leger, Andreas Decken, “Macrocyclic head-to-tail α-peptoids” Org. Lett. 16 (10) 2780-2783 (2014)

Miroslava Cuperlovic-Culf, Mohamed Touaibia, Patrick-Denis St-Coeur, Julie Poitras, Pier Jr Morin, and Adrian Culf “Metabolic effects of known and novel HDAC and SIRT inhibitors in glioblastomas independently or combined with temozolomide” Metabolites 4 807-830 (2014)

Miroslava Cuperlovic-Culf, Adrian S. Culf “Protein acetylation as an integral part of metabolism in cancer development and progression” American Journal of Cancer Review, 2, 6-28 (2014)

N. Lefort, A. Brown, V. Lloyd, R. Ouellette, M. Touaibia, A.S. Culf, M. Cuperlovic-Culf. “1H NMR analysis of the effect of dichloroacetate and allopurinol on breast cancers.” J. Pharmaceutical and Biomedical Analysis 93 77-85 (2014)

M. Cuperlovic-Culf, P. Jr Morin, A.S. Culf, M. Touaibia “Application of metabolomics in drug discovery, development and theranostics” Current Metabolomics. 1, 41-57 (2013)

M. Cuperlovic-Culf, A.S. Culf, M. Touaibia, N. LeFort “Targeting the last hallmark of cancer: Another attempt at “magic bullet” drugs targeting cancers’ metabolic phenotype” Frontiers in Oncology 8, 1-16 (2012) 

M. Cuperlovic-Culf, D. Ferguson, A.S. Culf, P. Morin, M. Touaibia, "1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics" J. Biol. Chem. 287 20164-20175 (2012) 

A.S. Culf, J.A. Melanson, R.J. Ouellette, G.G. Briand “Bis-imine primary amine protection of the dialkyltriamine, norpsermidine” Tetrahedron Lett. 53, 3301-3304 (2012) 

Site by: Spectacle Group